Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxycycline + medroxyprogesterone acetate
- Development stage
- Unknown
- Lead developer
- Fang Wang
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doxycycline + medroxyprogesterone acetate is a combination therapy being investigated for the treatment of chronic endometritis (CE) in patients with recurrent reproductive failure (RRF). Doxycycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, addressing the infectious etiology of CE. Medroxyprogesterone acetate (MPA) is a synthetic derivative of progesterone that acts as a potent agonist of the progesterone receptor. In this therapeutic context, MPA is used to modulate the endometrial environment, potentially enhancing the resolution of inflammation and improving endometrial receptivity for future pregnancies. The combination is currently being evaluated in a randomized controlled trial to determine if it offers superior clinical efficacy and pregnancy outcomes compared to doxycycline monotherapy.
- Other names
- Doxycycline combined with MedroxyprogesteroneDoxycycline + MPA
02
Targets
Bacterial RibosomePR (Progesterone receptor)3β-HSD (3β-Hydroxysteroid Dehydrogenase/Δ5-4 isomerase type 1)
Beyond the preview
Go deeper on doxycycline + medroxyprogesterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxycycline + medroxyprogesterone acetate.